We are pleased to announce our collaboration with Proton Intelligence, a company dedicated to transforming management of potassium to prevent hyperkalemia and hypokalemia for people living with chronic kidney disease (CKD) and congestive heart failure (CHF) through innovative technology.
Hyperkalemia, characterized by elevated potassium levels, affects more than 3.7 million people in the US alone. It is common in patients with CKD and CHF and can lead to life-threatening cardiac events. Proton Intelligence is developing the world’s first real-time, on-demand potassium monitoring wearable — aiming to equip clinicians with the tools to manage potassium safely and precisely in some of the most complex and vulnerable patient populations.
Our collaboration focuses on an early human feasibility study in dialysis patients, conducted under the leadership of Dr. Marat Fudim, MD, MHS, Advanced Heart Failure Specialist and Cardiologist at Duke University.
At Clinical Accelerator, we are committed to supporting groundbreaking medical innovations through partnerships with emerging medtech companies. Our collaboration with Proton Intelligence exemplifies our dedication to advancing innovative medical technologies through effective implementation of early human feasibility studies. We look forward to the advancements this partnership will bring to hyperkalemia management and patient care.